AbbVie, Anima Biotech Collaborate To Develop MRNA Modulators In Oncology, Immunology Targets

January 10, 2023 — 08:39 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - AbbVie Inc. (ABBV), and Anima Biotech (Anima) Tuesday announced a collaboration in mRNA biology modulators for three targets across Oncology and Immunology. As per the agreement, Anima will receive an upfront payment of $42 million with the potential for further milestones and royalties and up to $540 million in option fees and R&D milestones.

The discovery of mRNA biology modulators will be based on Anima's mRNA Lightning platform. The collaboration offers AbbVie exclusive rights to license and further develop and commercialize the programs.

Anima utilizes phenotypic screening with AI-driven elucidation of the mechanisms of action in the field of small molecule mRNA drug combines.

Jonathon Sedgwick, vice president and global head of discovery research of AbbVie said "Modulating mRNA biology with small molecules is a new approach and has the potential to address 'undruggable' targets with implications across multiple therapy areas."

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

AbbVie, Anima Biotech Collaborate To Develop MRNA Modulators In Oncology, Immunology Targets

Tags

Latest Articles